Page last updated: 2024-11-06

orsellinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Orsellinic acid is a natural product that is a precursor to several important natural products, including depsidones, depsides, and diphenyl ethers. It is a white crystalline solid with a melting point of 175-177 °C. Orsellinic acid can be synthesized by a variety of methods, including the decarboxylation of 2,4-dihydroxybenzoic acid. Orsellinic acid has been shown to have a variety of biological activities, including antifungal, antibacterial, and anti-inflammatory activities. It is also a key intermediate in the biosynthesis of the antibiotic griseofulvin. The study of orsellinic acid and its derivatives is important for understanding the biosynthesis of natural products and for developing new drugs.'

orsellinic acid: from the Sonoran desert endophytic fungus Chaetomium globosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

o-orsellinic acid : A dihydroxybenzoic acid that is 2,4-dihydroxybenzoic acid in which the hydrogen at position 6 is replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68072
CHEMBL ID457583
CHEBI ID32807
SCHEMBL ID522294
MeSH IDM0486377

Synonyms (67)

Synonym
BB 0218020
orsellinsaeure
orsellic acid
CHEBI:32807 ,
orsellinic acid
DIVK1C_006216
KBIO1_001160
SDCCGMLS-0066472.P001
SPECTRUM4_001598
SPECTRUM_000594
SPECTRUM5_000316
MEGXM0_000096
480-64-8
2,4-dihydroxy-6-methylbenzoic acid
C01839
4,6-dihydroxy-o-toluic acid
o-orsellinic acid
BSPBIO_002887
NCGC00095565-01
KBIOGR_002216
KBIO2_006210
KBIO2_003642
KBIO2_001074
KBIO3_002107
KBIOSS_001074
SPECPLUS_000120
SPBIO_000270
SPECTRUM2_000305
SPECTRUM3_001284
SPECTRUM300001
NCGC00095565-02
LMPK13010001
AKOS000349074
FT-0693806
CHEMBL457583
2,4-dihydroxy-6-methyl-benzoic acid
benzoic acid, 2,4-dihydroxy-6-methyl-
unii-11xla0494b
11xla0494b ,
orcinolcarboxylic acid
CCG-38582
4,6-dihydroxy-2-methylbenzoic acid
2,4-dihydroxy-6-methylbenzenecarboxylic acid
6-methyl- -resorcylic acid
AM20040543
6-methyl-.beta.-resorcylic acid
o-orsellinic acid [mi]
SCHEMBL522294
.beta.-resorcylic acid, 6-methyl-
DTXSID20197385
mfcd00210536
sr-05000002400
SR-05000002400-1
bdbm50104645
BBL103122
STL556932
2,4-dihydroxy-6-methyl benzoic acid
6X7 ,
Q414421
DS-17030
orsellinicacid
6-methyl-beta-resorcylic acid; orcinolcarboxylic acid
CS-0023315
6-methyl--resorcylic acid; orcinolcarboxylic acid
HY-N3126
AB92942
SY110288

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" decussata and their plasma-related bioavailability were also investigated using LC-ESI-MS/MS."( New Insights into the Biological Activity of Lichens: Bioavailable Secondary Metabolites of Umbilicaria decussata as Potential Anticoagulants.
Javad Davarpanah, S; Vaez, M, 2021
)
0.62
" The bioavailability of OA is hampered by its hydrophobic nature."( Orsellinic acid-loaded chitosan nanoparticles in gelatin/nanohydroxyapatite scaffolds for bone formation in vitro.
Balagangadharan, K; Lavanya, K; Selvamurugan, N; Yadav, LR, 2022
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dihydroxybenzoic acidAny member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00890.003245.467312,589.2998AID2517
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)100.00000.06002.28897.8000AID1235896
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)100.00000.08002.50619.8500AID1235896
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1866143Antifungal activity against Candida albicans DSM 1665 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID401699Cytotoxicity against human MCF7 cells at 10 ug/mL by MTT assay2005Journal of natural products, May, Volume: 68, Issue:5
Globosumones A-C, cytotoxic orsellinic acid esters from the Sonoran desert endophytic fungus Chaetomium globosum.
AID1866154Cytotoxicity against mouse L929 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1866153Antibacterial activity against Staphylococcus aureus DSM 346 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID469329Inhibition of PTP1B mediated pNPP hydrolysis at 178 uM2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Isolation of the protein tyrosine phosphatase 1B inhibitory metabolite from the marine-derived fungus Cosmospora sp. SF-5060.
AID1235896Inhibition of alpha-glucosidase (unknown origin) pre-incubated for 20 mins before p-nitrophenyl glycoside substrate addition2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Polyketides with α-Glucosidase Inhibitory Activity from a Mangrove Endophytic Fungus, Penicillium sp. HN29-3B1.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1866151Antifungal activity against Rhodotorula glutinis DSM 10134 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID1866148Antibacterial activity against Mycobacterium smegmatis ATCC 700084 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866155Cytotoxicity against human KB 3-1 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1434783Antifouling activity against Bugula neritina larvae assessed as inhibition of larval settlement at 25 ug/ml after 1 hr by dissecting microscopy relative to control2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus versicolor SCSIO 41502.
AID401700Cytotoxicity against human NCI-H460 cells at 10 ug/mL by MTT assay2005Journal of natural products, May, Volume: 68, Issue:5
Globosumones A-C, cytotoxic orsellinic acid esters from the Sonoran desert endophytic fungus Chaetomium globosum.
AID471373Cytotoxicity against human HCT116 cells at <=100 uM after 48 hrs by MTT assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID401698Cytotoxicity against human MIAPaCa2 cells at 10 ug/mL2005Journal of natural products, May, Volume: 68, Issue:5
Globosumones A-C, cytotoxic orsellinic acid esters from the Sonoran desert endophytic fungus Chaetomium globosum.
AID1866146Antibacterial activity against Micrococcus luteus DSM 1790 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866149Antifungal activity against Pichia anomala DSM 6766 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID471375Cytotoxicity against human Jurkat T cells at <=100 uM after 48 hrs by MTT assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID1866150Antibacterial activity against Pseudomonas aeruginosa PA 14 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1434780Antioxidant activity assessed as DPPH radical scavenging activity at 100 ug/ml after 30 mins2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus versicolor SCSIO 41502.
AID401697Cytotoxicity against human SF268 cells at 10 ug/mL2005Journal of natural products, May, Volume: 68, Issue:5
Globosumones A-C, cytotoxic orsellinic acid esters from the Sonoran desert endophytic fungus Chaetomium globosum.
AID1866144Antibacterial activity against Chromobacterium violaceum DSM 30191 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1394618Inhibition of recombinant N-terminal His6 tagged SUMO-fused Trypanosoma brucei brucei TC221 TAO MTS deletion mutant expressed in Escherichia coli FN102 preincubated for 2 mins followed by ubiquinol-1 addition measured over 2 mins by double beam-dual wavel2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibition of trypanosome alternative oxidase without its N-terminal mitochondrial targeting signal (ΔMTS-TAO) by cationic and non-cationic 4-hydroxybenzoate and 4-alkoxybenzaldehyde derivatives active against T. brucei and T. congolense.
AID1866147Antifungal activity against Mucor hiemalis DSM 2656 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID471374Cytotoxicity against human MCF7 cells at <=100 uM after 48 hrs by MTT assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID471376Cytotoxicity against human CCRF-CEM cells at <=100 uM after 48 hrs by MTT assay2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID1866145Antibacterial activity against Escherichia coli DSM 1116 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID401696Cytotoxicity against human WI38 cells at 10 ug/mL2005Journal of natural products, May, Volume: 68, Issue:5
Globosumones A-C, cytotoxic orsellinic acid esters from the Sonoran desert endophytic fungus Chaetomium globosum.
AID1866152Antifungal activity against Schizosaccharomyces pombe DSM 70572 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID1866142Antibacterial activity aginst Bacillus subtilis DSM 10 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.70)18.7374
1990's0 (0.00)18.2507
2000's9 (16.67)29.6817
2010's31 (57.41)24.3611
2020's12 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.39 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index43.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (7.02%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (92.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]